BriaCell Therapeutics (BCTX) vs China Pharma (CPHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
China Pharma (CPHI) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 51.8% versus a loss of 69.2%. Over five years, BCTX leads with a -95.2% price change compared with -99.7% for CPHI. China Pharma is the larger company by market cap ($41.3 million vs $34.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | CPHI |
|---|---|---|
| Share price | $3.92 | $0.96 |
| Market cap | $34.10M | $41.30M |
| 1-day change | -2.00% | +12.94% |
| YTD return | -44.87% | -20.66% |
| 1-year return | -69.18% | -51.76% |
| 5-year return | -95.21% | -99.65% |
| EPS (TTM) | $-0.92 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $19.19 |
| 52-week low | $2.60 | $0.38 |
| Distance from 52-week high | -73.30% | -95.00% |
| Average volume | 278.91K | 5.81M |
| Shares outstanding | 8.70M | 43.02M |
| Employees | — | 215 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPHI has outperformed BCTX by 17.4 percentage points over the past year.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Healthcare · Biotechnology
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Healthcare · Drug Manufacturers - Specialty & Generic · 215 employees
BCTX vs CPHI FAQ
Which is bigger, BriaCell Therapeutics or China Pharma?
China Pharma (CPHI) is larger, with a market capitalization of $41.30M compared with $34.10M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or CPHI?
CPHI returned -51.76% over the past 12 months, compared with -69.18% for BCTX (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and China Pharma in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for BriaCell Therapeutics and Drug Manufacturers - Specialty & Generic for China Pharma.